Innovations in Healthcare: Updates on Drug Trials, Transdermal Products, and Digital Health Platforms

Ascentage Pharma is conducting a Phase III trial for the Bcl-2 inhibitor lisaftoclax in combination with azacitidine for higher-risk myelodysplastic syndrome patients. Nutriband Inc. will be presenting at the Emerging Growth Conference with a focus on abuse-deterrent fentanyl patches. MyAbroadMDs is a digital platform connecting travelers with global medical care, offering memberships for customized healthcare access. NRx Pharmaceuticals provided financial updates and progress in developing therapeutics for central nervous system disorders.